Table 4.
Characteristics | Group A, <7.5% (n = 835)* | Group B, ⩾7.5 to ⩽8.5% (n = 3605)** | Group C, >8.5% (n = 1119) # | P value |
---|---|---|---|---|
Age (y) | 49.0 (42.0-59.0) | [n = 3599] 49 (41.0-58.0) | 47.0 (55.0-63.0) | .092 a , .001b,c |
Age group (y), n (%) | ||||
⩾20-⩽40 | 179 (21.4) | 889 (24.7) | 128 (11.4) | <.001a,b,c |
>40-⩽60 | 490 (58.7) | 2067 (57.4) | 648 (57.4) | |
>60-⩽80 | 166 (19.9) | 643 (17.9) | 343 (30.7) | |
Sex, n (%) | [n = 803] | [n = 3518] | [n = 1102] | .186 |
Men | 480 (59.8) | 2216 (63.0) | 700 (63.5) | |
Women | 323 (40.2) | 1302 (37.0) | 402 (36.5) | |
BMI (kg/m2) | [n = 742] 26.7 (24.3-29.5) | [n = 3183] 27.7 (25.3-30.4) | [n = 998] 28.7 (26.0-31.0) | <.001a,b,c |
Location, n (%) | [n = 600] | [n = 2736] | [n = 760] | .137 |
Urban | 124 (20.7) | 598 (21.9) | 141 (18.6) | |
Rural | 476 (79.3) | 2138 (78.1) | 619 (81.4) | |
Duration of diabetes (mo) | [n = 829] 36.0 (12.0-60.0) | [n = 3581] 36.0 (12.0-72.0) | [n = 1112] 60.0 (24.0-96.0) | <.001a,b,c |
Duration of high-dose treatment (mo) | [n = 692] 12.0 (6.0-24.0) | [n = 3397] 20.0 (6.0-36.0) | [n = 987] 24.0 (12.0-48.0) | .005 a , <0.001b,c |
Mean HbA1c level (%) | [n = 301] | [n = 1481] | [n = 417] | — |
Previous | 7.5 (0.6) | 8.1 (0.6) | 9.3 (0.8) | |
Current | 6.6 (0.5) | 7.1 (0.6) | 7.8 (0.8) | |
Mean change [95% CI]; P value | 0.9 [0.8-0.9]; <.001 | 1.0 [1.0-1.1]; <.001 | 1.4 [1.3-1.4]; <.001 | |
Weight change (kg), n (%) | [n = 599] | [n = 2728] | [n = 793] | |
Increase | ||||
0-2 | 109 (18.2) | 239 (8.7) | 96 (12.9) | — |
2-4 | 28 (4.7) | 151 (5.5) | 54 (6.8) | |
>4 | 0 | 13 (0.5) | 10 (1.3) | |
Decrease | ||||
0-2 | 314 (52.4) | 1708 (62.6) | 349 (44.0) | — |
2-4 | 134 (22.4) | 541(19.8) | 215 (27.1) | |
>4 | 14 (2.3) | 76 (2.7) | 69 (8.7) |
Abbreviations: BMI, body mass index; HbA1c, glycated hemoglobin; IQR, interquartile range.
Data shown as median (IQR), unless otherwise specified.
Group A versus B; bgroup A versus C; cgroup B versus C.
n = 835. **n = 3605. #n = 1119, unless otherwise specified.